伊洛前列素输注降低系统性硬化症患者缺氧和炎症的血清细胞因子和激素。

Iloprost infusion reduces serological cytokines and hormones of hypoxia and inflammation in systemic sclerosis patients.

机构信息

Department of Translational and Precision Medicine, Sapienza University of Rome, Viale Dell'Università 37, 00185, Rome, Italy.

Department of Public Health, Nephrology Unit, University Federico II, 80138, Naples, Italy.

出版信息

Clin Exp Med. 2024 May 22;24(1):109. doi: 10.1007/s10238-024-01374-4.

DOI:10.1007/s10238-024-01374-4

PMID:38777916

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11111538/

Abstract

INTRODUCTION

Systemic sclerosis (SSc) is characterized by microvascular damage of skin and internal organs with chronic hypoxia and release of cytokines and hormones such as neutrophil gelatinase-associated lipocalin (NGAL), fibroblast growth factor-23 (FGF-23) and Klotho. Aim of the study was to evaluate FGF-23, Klotho and NGAL serum levels in SSc patients and healthy controls (HC) and to evaluate serum levels changes of FGF-23, Klotho and NGAL after Iloprost.

METHODS

Twenty-one SSc patients and 20 HC were enrolled. In SSc patients, peripheral venous blood samples were collected at the first day before the autumn Iloprost infusion (t0), 60 min (t1) and 14 days after Iloprost infusion (t2).

RESULTS

SSc patients had higher serum level of FGF-23 [18.7 ± 6.4 pg/ml versus 3.6 ± 2.2 pg/ml, p < 0.001], Klotho [5.1 ± 0.8 pg/ml versus 2.3 ± 0.6 pg/ml, p < 0.001] and NGAL [20.9 ± 2.6 pg/ml versus 14.5 ± 1.7 pg/ml, p < 0.001] than HC. Iloprost infusion reduces serum level of FGF-23 (18.7 ± 6.4 pg/ml versus 10.4 ± 5.5 pg/ml, p < 0.001), Klotho (5.1 ± 0.8 pg/ml versus 2.5 ± 0.6 pg/ml, p < 0.001) and NGAL (20.9 ± 2.6 pg/ml versus 15.1 ± 2.3 pg/ml, p < 0.001) between t0 and t1. The Iloprost infusion reduces serum level of FGF-23 (18.7 ± 6.4 pg/ml versus 6.6 ± 5.1 pg/ml), Klotho (5.1 ± 0.8 pg/ml versus 2.3 ± 0.4 pg/ml) and NGAL (20.9 ± 2.6 pg/ml versus 15.5 ± 1.9 pg/ml) between t0 and t2.

CONCLUSIONS

SSc patients had higher FGF-23, Klotho and NGAL than HC. Iloprost reduces serum levels of FGF-23, Klotho and NGAL.

摘要

简介

系统性硬化症（SSc）的特征是皮肤和内脏器官的微血管损伤，伴有慢性缺氧以及中性粒细胞明胶酶相关脂质运载蛋白（NGAL）、成纤维细胞生长因子 23（FGF-23）和 Klotho 等细胞因子和激素的释放。本研究旨在评估 SSc 患者和健康对照者（HC）的 FGF-23、Klotho 和 NGAL 血清水平，并评估 Iloprost 后 FGF-23、Klotho 和 NGAL 血清水平的变化。

方法

纳入 21 例 SSc 患者和 20 例 HC。在 SSc 患者中，于秋季 Iloprost 输注前第 1 天（t0）、输注后 60 分钟（t1）和 14 天（t2）采集外周静脉血样。

结果

SSc 患者的 FGF-23 [18.7±6.4 pg/ml 与 3.6±2.2 pg/ml，p<0.001]、Klotho [5.1±0.8 pg/ml 与 2.3±0.6 pg/ml，p<0.001] 和 NGAL [20.9±2.6 pg/ml 与 14.5±1.7 pg/ml，p<0.001] 血清水平均高于 HC。Iloprost 输注降低了 FGF-23（18.7±6.4 pg/ml 与 10.4±5.5 pg/ml，p<0.001）、Klotho（5.1±0.8 pg/ml 与 2.5±0.6 pg/ml，p<0.001）和 NGAL（20.9±2.6 pg/ml 与 15.1±2.3 pg/ml，p<0.001）的血清水平，t0 与 t1 之间存在差异。Iloprost 输注降低了 FGF-23（18.7±6.4 pg/ml 与 6.6±5.1 pg/ml）、Klotho（5.1±0.8 pg/ml 与 2.3±0.4 pg/ml）和 NGAL（20.9±2.6 pg/ml 与 15.5±1.9 pg/ml）的血清水平，t0 与 t2 之间存在差异。